{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:25:48Z","timestamp":1785446748215,"version":"3.56.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93634-w","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:50:54Z","timestamp":1742219454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukaemia patient cohort"],"prefix":"10.1038","volume":"15","author":[{"given":"V. L.","family":"Kenmogne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Takundwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. E.","family":"Nweke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Monchusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Du Toit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Philip-Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-1893","authenticated-orcid":false,"given":"P. N.","family":"Fru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. B.","family":"Thimiri Govinda Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"93634_CR1","first-page":"85","volume":"79","author":"X Ma","year":"2006","unstructured":"Ma, X. & Yu, H. Global burden of cancer. Yale J. Biol. Med. 79, 85\u201394 (2006).","journal-title":"Yale J. Biol. Med."},{"key":"93634_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"93634_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(22)00270-4","volume":"23","author":"F Bray","year":"2022","unstructured":"Bray, F., Parkin, D. M., African Cancer Registry Network. Cancer in sub-Saharan Africa in 2020: A review of current estimates of the national burden, data gaps, and future needs. Lancet Oncol. 23, 719\u20137288 (2022).","journal-title":"Lancet Oncol."},{"key":"93634_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.839835","author":"R Sharma","year":"2022","unstructured":"Sharma, R. et al. Mapping cancer in Africa: A comprehensive and comparable characterization of 34 cancer types using estimates from GLOBOCAN 2020. Front. Public Health https:\/\/doi.org\/10.3389\/fpubh.2022.839835 (2022).","journal-title":"Front. Public Health"},{"key":"93634_CR5","unstructured":"Coordinator, C. S. M. Cancer Statistics. CANSA - The Cancer Association of South Africa https:\/\/cansa.org.za\/south-african-cancer-statistics\/ (2012)."},{"key":"93634_CR6","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S1470-2045(15)00162-X","volume":"16","author":"E Singh","year":"2015","unstructured":"Singh, E. et al. Establishment of a cancer surveillance programme: The South African experience. Lancet Oncol. 16, e414\u2013e421 (2015).","journal-title":"Lancet Oncol."},{"key":"93634_CR7","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1016\/j.clml.2020.12.006","volume":"21","author":"R Shein","year":"2021","unstructured":"Shein, R. et al. Outcomes for patients with acute promyelocytic leukemia in South Africa. Clin. Lymphoma Myeloma Leuk. 21, e348\u2013e352 (2021).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"93634_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Acute myeloid leukemia: Current progress and future directions. Blood Cancer J. 11, 1\u201325 (2021).","journal-title":"Blood Cancer J."},{"key":"93634_CR9","unstructured":"Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense | Blood Cancer Journal. https:\/\/www.nature.com\/articles\/s41408-023-00823-9."},{"key":"93634_CR10","first-page":"6","volume":"5","author":"F Musaigwa","year":"2021","unstructured":"Musaigwa, F., Grewal, R., Abayomi, A. & Swanepoel, C. C. Chronic lymphocytic leukaemia trends and features at a tertiary hospital in South Africa (2011\u20132016). South Afr. J. Oncol. 5, 6 (2021).","journal-title":"South Afr. J. Oncol."},{"key":"93634_CR11","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.drup.2024.101195","volume":"79","author":"X Ma","year":"2025","unstructured":"Ma, X. et al. Research progress on gene mutations and drug resistance in leukemia. Drug Resist. Updates 79, 101195 (2025).","journal-title":"Drug Resist. Updates"},{"key":"93634_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-023-01722-5","volume":"9","author":"P Ayuda-Dur\u00e1n","year":"2023","unstructured":"Ayuda-Dur\u00e1n, P. et al. Standardized assays to monitor drug sensitivity in hematologic cancers. Cell Death Discov. 9, 1\u201313 (2023).","journal-title":"Cell Death Discov."},{"key":"93634_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.slasd.2022.11.003","volume":"28","author":"M Feodoroff","year":"2023","unstructured":"Feodoroff, M. et al. Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates. SLAS Discov. 28, 36\u201341 (2023).","journal-title":"SLAS Discov."},{"key":"93634_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/5584_2021_622","volume-title":"Cell Biology and Translational Medicine, Volume 12: Stem Cells in Development and Disease","author":"EE Nweke","year":"2021","unstructured":"Nweke, E. E., Thimiri, D. B. & Raj, G. Drug sensitivity and drug repurposing platform for cancer precision medicine. In Cell Biology and Translational Medicine, Volume 12: Stem Cells in Development and Disease (ed. Turksen, Kursad) 47\u201353 (Springer, 2021). https:\/\/doi.org\/10.1007\/5584_2021_622."},{"key":"93634_CR15","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41375-020-0846-5","volume":"34","author":"M Lukas","year":"2020","unstructured":"Lukas, M. et al. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia 34, 2934\u20132950 (2020).","journal-title":"Leukemia"},{"key":"93634_CR16","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1182\/blood-2018-99-110357","volume":"132","author":"TG Raj","year":"2018","unstructured":"Raj, T. G. et al. In-vitro drug sensitivity screening in chronic lymphocytic leukemia (CLL) primary patient samples identifies drug candidates for precision cancer therapy. Blood 132, 4676\u20134676 (2018).","journal-title":"Blood"},{"key":"93634_CR17","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/1878-0261.13191","volume":"16","author":"M Giliberto","year":"2022","unstructured":"Giliberto, M. et al. Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Mol. Oncol. 16, 1241\u20131258 (2022).","journal-title":"Mol. Oncol."},{"key":"93634_CR18","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1182\/blood-2018-99-110669","volume":"132","author":"DBB Thimiri Govinda Raj","year":"2018","unstructured":"Thimiri Govinda Raj, D. B. B. et al. Drug sensitivity screening on multiple myeloma for precision cancer therapy. Blood 132, 4677\u20134677 (2018).","journal-title":"Blood"},{"key":"93634_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-023-00463-z","volume":"7","author":"E \u00c5kerlund","year":"2023","unstructured":"\u00c5kerlund, E. et al. The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients. npj Precis. Onc. 7, 1\u201313 (2023).","journal-title":"npj Precis. Onc."},{"key":"93634_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41375-019-0569-7","volume":"34","author":"SS Sk\u00e5nland","year":"2020","unstructured":"Sk\u00e5nland, S. S. et al. An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL. Leukemia 34, 478\u2013487 (2020).","journal-title":"Leukemia"},{"key":"93634_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41467-022-35624-4","volume":"14","author":"BS Tislevoll","year":"2023","unstructured":"Tislevoll, B. S. et al. Early response evaluation by single cell signaling profiling in acute myeloid leukemia. Nat. Commun. 14, 115 (2023).","journal-title":"Nat. Commun."},{"key":"93634_CR22","doi-asserted-by":"publisher","first-page":"100654","DOI":"10.1016\/j.crmeth.2023.100654","volume":"3","author":"AN Andersen","year":"2023","unstructured":"Andersen, A. N. et al. Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling. Cell. Rep. Methods 3, 100654 (2023).","journal-title":"Cell. Rep. Methods"},{"key":"93634_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.exphem.2015.08.009","volume":"44","author":"SE Sylvan","year":"2016","unstructured":"Sylvan, S. E. et al. Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study. Exp. Hematol. 44, 38-49.e1 (2016).","journal-title":"Exp. Hematol."},{"key":"93634_CR24","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","volume":"108","author":"H Kuusanm\u00e4ki","year":"2023","unstructured":"Kuusanm\u00e4ki, H. et al. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica 108, 1768\u20131781 (2023).","journal-title":"Haematologica"},{"key":"93634_CR25","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1038\/bcj.2015.30","volume":"5","author":"PO Pietarinen","year":"2015","unstructured":"Pietarinen, P. O. et al. Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. Blood Cancer J. 5, e309 (2015).","journal-title":"Blood Cancer J."},{"key":"93634_CR26","doi-asserted-by":"publisher","first-page":"E7554","DOI":"10.1073\/pnas.1703094114","volume":"114","author":"SE Kurtz","year":"2017","unstructured":"Kurtz, S. E. et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc. Natl. Acad. Sci. 114, E7554\u2013E7563 (2017).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"93634_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0145-2126(95)00127-1","volume":"20","author":"AG Bosanquet","year":"1996","unstructured":"Bosanquet, A. G. & Bell, P. B. Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leuk. Res. 20, 143\u2013153 (1996).","journal-title":"Leuk. Res."},{"key":"93634_CR28","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","volume":"108","author":"H Kuusanm\u00e4ki","year":"2023","unstructured":"Kuusanm\u00e4ki, H. et al. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica 108, 1768\u20131781 (2023).","journal-title":"Haematologica"},{"key":"93634_CR29","doi-asserted-by":"publisher","first-page":"101739","DOI":"10.1016\/j.canep.2020.101739","volume":"67","author":"E Okoturo","year":"2020","unstructured":"Okoturo, E. et al. Genetic variants association with cancers in African-based populations: A systematic review. Cancer Epidemiol. 67, 101739 (2020).","journal-title":"Cancer Epidemiol."},{"key":"93634_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.606400","volume":"10","author":"SO Rotimi","year":"2021","unstructured":"Rotimi, S. O., Rotimi, O. A. & Salhia, B. A review of cancer genetics and genomics studies in Africa. Front. Oncol. 10, 606400 (2021).","journal-title":"Front. Oncol."},{"key":"93634_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01207-3","volume":"15","author":"C Bonolo de Campos","year":"2025","unstructured":"Bonolo de Campos, C. et al. Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry. Blood Cancer J. 15, 1\u20138 (2025).","journal-title":"Blood Cancer J."},{"key":"93634_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/5584_2022_744","volume-title":"Cell Biology and Translational Medicine, Volume 19: Perspectives in Diverse Human Diseases and Their Therapeutic Options","author":"VL Kenmogne","year":"2023","unstructured":"Kenmogne, V. L. et al. Application of drug repurposing-based precision medicine platform for leukaemia patient treatment. In Cell Biology and Translational Medicine, Volume 19: Perspectives in Diverse Human Diseases and Their Therapeutic Options (ed. Turksen, Kursad) 115\u2013126 (Springer Nature Switzerland, 2023). https:\/\/doi.org\/10.1007\/5584_2022_744."},{"key":"93634_CR33","doi-asserted-by":"publisher","first-page":"101204","DOI":"10.1016\/j.xpro.2022.101204","volume":"3","author":"A Efthymiou","year":"2022","unstructured":"Efthymiou, A. et al. Isolation and freezing of human peripheral blood mononuclear cells from pregnant patients. STAR Protoc. 3, 101204 (2022).","journal-title":"STAR Protoc."},{"key":"93634_CR34","doi-asserted-by":"publisher","first-page":"9129","DOI":"10.3390\/ijms22179129","volume":"22","author":"CM Hope","year":"2021","unstructured":"Hope, C. M. et al. Optimization of blood handling and peripheral blood mononuclear cell cryopreservation of low cell number samples. Int. J. Mol. Sci. 22, 9129 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"93634_CR35","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","volume":"36","author":"S Potdar","year":"2020","unstructured":"Potdar, S. et al. Breeze: An integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics 36, 3602\u20133604 (2020).","journal-title":"Bioinformatics"},{"key":"93634_CR36","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.12688\/f1000research.20590.2","volume":"8","author":"MC Ryan","year":"2020","unstructured":"Ryan, M. C. et al. Interactive clustered heat map builder: An easy web-based tool for creating sophisticated clustered heat maps. F1000Res 8, 1750 (2020).","journal-title":"F1000Res"},{"key":"93634_CR37","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"93634_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513 (2015).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"93634_CR39","doi-asserted-by":"publisher","first-page":"13891","DOI":"10.1038\/srep13891","volume":"5","author":"BT Mott","year":"2015","unstructured":"Mott, B. T. et al. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Sci. Rep. 5, 13891 (2015).","journal-title":"Sci. Rep."},{"key":"93634_CR40","doi-asserted-by":"publisher","first-page":"e743599b","DOI":"10.1097\/01.HS9.0000969356.74359.9b","volume":"7","author":"L Miranda Santana","year":"2023","unstructured":"Miranda Santana, L. et al. P613: Analysis of ex-vivo response to single drugs and drug combinations in chronic lymphocytic leukemia patient samples. HemaSphere 7, e743599b (2023).","journal-title":"HemaSphere"},{"key":"93634_CR41","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2014).","journal-title":"Sci. Rep."},{"key":"93634_CR42","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1182\/blood-2018-99-110357","volume":"132","author":"DB Thimiri Govinda Raj","year":"2018","unstructured":"Thimiri Govinda Raj, D. B. et al. In-vitro drug sensitivity screening in chronic lymphocytic leukemia (CLL) primary patient samples identifies drug candidates for precision cancer therapy. Blood 132, 4676 (2018).","journal-title":"Blood"},{"key":"93634_CR43","doi-asserted-by":"publisher","first-page":"14646","DOI":"10.3390\/ijms241914646","volume":"24","author":"RU Din","year":"2023","unstructured":"Din, R. U. et al. Bortezomib is effective in the treatment of T lymphoblastic leukaemia by inducing DNA damage, WEE1 downregulation, and mitotic catastrophe. Int. J. Mol. Sci. 24, 14646 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"93634_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jcyt.2020.09.010","volume":"23","author":"JY Story","year":"2021","unstructured":"Story, J. Y. et al. Bortezomib enhances cytotoxicity of ex vivo expanded gamma delta (\u03b3\u03b4) T cells against AML and T-ALL. Cytotherapy 23, 12\u201324 (2021).","journal-title":"Cytotherapy"},{"key":"93634_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","volume":"19","author":"P Robak","year":"2019","unstructured":"Robak, P. & Robak, T. Bortezomib for the treatment of hematologic malignancies: 15 years later. Drugs R D 19, 73\u201392 (2019).","journal-title":"Drugs R D"},{"key":"93634_CR46","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3892\/ijo.2014.2792","volume":"46","author":"M F\u00fcller","year":"2015","unstructured":"F\u00fcller, M. et al. 5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. Int. J. Oncol. 46, 1192\u20131204 (2015).","journal-title":"Int. J. Oncol."},{"key":"93634_CR47","doi-asserted-by":"publisher","first-page":"19844","DOI":"10.1021\/acsomega.0c02832","volume":"5","author":"L Xia","year":"2020","unstructured":"Xia, L. et al. Honokiol-Chlorambucil co-prodrugs selectively enhance the killing effect through STAT3 binding on lymphocytic leukemia cells in vitro and in vivo. ACS Omega 5, 19844\u201319852 (2020).","journal-title":"ACS Omega"},{"key":"93634_CR48","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/1535-7163.MCT-12-1197","volume":"12","author":"DJP Bates","year":"2013","unstructured":"Bates, D. J. P., Danilov, A. V., Lowrey, C. H. & Eastman, A. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. Mol. Cancer Ther. 12, 1504\u20131514 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"93634_CR49","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/1878-0261.12086","volume":"11","author":"M Kolberg","year":"2017","unstructured":"Kolberg, M. et al. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. Mol. Oncol. 11, 1156\u20131171 (2017).","journal-title":"Mol. Oncol."},{"key":"93634_CR50","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1038\/s41467-019-09917-0","volume":"10","author":"CD Drenberg","year":"2019","unstructured":"Drenberg, C. D. et al. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nat. Commun. 10, 2189 (2019).","journal-title":"Nat. Commun."},{"key":"93634_CR51","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly, D. et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40, 850-864.e9 (2022).","journal-title":"Cancer Cell"},{"key":"93634_CR52","first-page":"3877","volume":"130","author":"P Garrido Castro","year":"2017","unstructured":"Garrido Castro, P. et al. Irinotecan induces complete remission in MLL -rearranged acute lymphoblastic leukemia xenografts. Blood 130, 3877 (2017).","journal-title":"Blood"},{"key":"93634_CR53","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-14-2888","volume":"21","author":"N Daver","year":"2015","unstructured":"Daver, N. et al. A phase I\/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed\/refractory acute lymphoblastic leukemia. Clin. Cancer Res. 21, 2704\u20132714 (2015).","journal-title":"Clin. Cancer Res."},{"key":"93634_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-024-00510-9","volume":"13","author":"M Mirzaie","year":"2024","unstructured":"Mirzaie, M. et al. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy\/toxicity integration and bipartite network modeling. Oncogenesis 13, 1\u201312 (2024).","journal-title":"Oncogenesis"},{"key":"93634_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-3-642-88125-1_12","volume-title":"Rubidomycin: A New Agent against Cancer","author":"J Bernard","year":"1969","unstructured":"Bernard, J., Paul, R., Boiron, M., Jacquillat, C. & Maral, R. Combination therapy in the treatment of acute leukemia. In Rubidomycin: A New Agent against Cancer (eds Bernard, J. et al.) 125\u2013143 (Springer, Berlin, 1969)."},{"key":"93634_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/1097-0142(197707)40:1<20::AID-CNCR2820400106>3.0.CO;2-W","volume":"40","author":"AS Spiers","year":"1977","unstructured":"Spiers, A. S. et al. Multiple-drug chemotherapy for acute leukemia The TRAMPCOL regimen: Results in 86 patients. Cancer 40, 20\u201329 (1977).","journal-title":"Cancer"},{"key":"93634_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjh.19519","volume":"205","author":"W-Y Jen","year":"2024","unstructured":"Jen, W.-Y. et al. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br. J. Haematol. 205, 30\u201347 (2024).","journal-title":"Br. J. Haematol."},{"key":"93634_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-024-00510-9","volume":"13","author":"M Mirzaie","year":"2024","unstructured":"Mirzaie, M. et al. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy\/toxicity integration and bipartite network modeling. Oncogenesis 13, 1\u201312 (2024).","journal-title":"Oncogenesis"},{"key":"93634_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/2643-3230.BCD-23-0067","volume":"5","author":"E Mason-Osann","year":"2024","unstructured":"Mason-Osann, E., Pomeroy, A. E., Palmer, A. C. & Mettetal, J. T. Synergistic Drug combinations promote the development of resistance in acute myeloid leukemia. Blood Cancer Discov. 5, 95\u2013105 (2024).","journal-title":"Blood Cancer Discov."},{"key":"93634_CR60","first-page":"101687","volume":"5","author":"DJ Vis","year":"2024","unstructured":"Vis, D. J. et al. A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level. CR Med 5, 101687 (2024).","journal-title":"CR Med"},{"key":"93634_CR61","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00277-016-2774-z","volume":"95","author":"H Park","year":"2016","unstructured":"Park, H. et al. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. Ann. Hematol. 95, 1777\u20131786 (2016).","journal-title":"Ann. Hematol."},{"key":"93634_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/1099-1069(200012)18:4<141::AID-HON666>3.0.CO;2-#","volume":"18","author":"SA Johnson","year":"2000","unstructured":"Johnson, S. A. & Thomas, W. Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies. Hematol. Oncol. 18, 141\u2013153 (2000).","journal-title":"Hematol. Oncol."},{"key":"93634_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1593\/neo.101334","volume":"13","author":"B Canu","year":"2011","unstructured":"Canu, B. et al. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia 13, 217\u2013229 (2011).","journal-title":"Neoplasia"},{"key":"93634_CR64","doi-asserted-by":"publisher","first-page":"S1613","DOI":"10.21037\/tcr.2017.10.07","volume":"6","author":"G Kichenadasse","year":"2017","unstructured":"Kichenadasse, G., Mangoni, A. & Miners, J. Combination of small-molecule kinase inhibitors and irinotecan in cancer clinical trials: efficacy and safety considerations. Transl. Cancer Res. 6, S1613 (2017).","journal-title":"Transl. Cancer Res."},{"key":"93634_CR65","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2217\/fon-2018-0468","volume":"15","author":"T Sacha","year":"2019","unstructured":"Sacha, T. & Saglio, G. Nilotinib in the treatment of chronic myeloid leukemia. Future Oncol. 15, 953\u2013965 (2019).","journal-title":"Future Oncol."},{"key":"93634_CR66","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.3390\/ijms21144919","volume":"21","author":"M Kciuk","year":"2020","unstructured":"Kciuk, M., Marciniak, B. & Kontek, R. Irinotecan\u2014Still an important player in cancer chemotherapy: A comprehensive overview. Int. J. Mol. Sci. 21, 4919 (2020).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93634-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T01:28:36Z","timestamp":1742261316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93634-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93634"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93634-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"16 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9160"}}